Flag of the European Union EU Clinical Trials Register Help

Clinical trials for patients with NAFLD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    56 result(s) found for: patients with NAFLD. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-003791-12 Sponsor Protocol Number: 12345 Start Date*: 2013-10-30
    Sponsor Name:Helsinki University
    Full Title: SIGNAL TRANSDUCTION IN NAFLD
    Medical condition: No significant disease other than obesity/type 2 diabetes/hypertension/NAFLD
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003231-46 Sponsor Protocol Number: 0001 Start Date*: 2005-11-04
    Sponsor Name:Dept of Internal Medicine IV, Med Uni Vienna
    Full Title: Changes in hepatic lipid content assessed by MR Spectroscopy in patients with non-alcoholic fatty liver disease (NAFLD) under standard therapy (reduction diet and regular aerobic exercise) with and...
    Medical condition: Nonalcoholic fatty liver disease (NAFLD) is a potentially progressive liver disease, leading to cirrhosis in up to 26% of affected patients and rarely hepatocellular carcinoma. Several studies have...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005531-28 Sponsor Protocol Number: Urso in Obese Start Date*: 2008-04-03
    Sponsor Name:Hanns-Ulrich Marschall
    Full Title: Ursodeoxycholic Acid in Morbidly Obese Patients Before Bariatric Surgery
    Medical condition: Patients with morbid obesity (MB) are investigated. MB is very frequently (90%) associated with non-alcoholic fatty liver disease (NAFLD) comprising a spectrum reaching from steatosis (NAFL) over s...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029530 Non-alcoholic fatty liver LLT
    Population Age: Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003010-17 Sponsor Protocol Number: - Start Date*: 2011-07-07
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Randomized double-blind intervention trial to assess the efficacy of vitamin D3 supplementation vs placebo in reducing hepatic steato-inflammation and cardio-metabolic risk profile in patients affe...
    Medical condition: Patients affected by type 2 diabetes and non alcoholic fatty liver disease- non alcoholic steato-hepatitis (NAFLD/NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002253-29 Sponsor Protocol Number: CEC-11/NAS Start Date*: 2022-03-08
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of ZED1227 capsules with placebo in the treatment of non-alcoholic fatty liver disease (NAFLD) wi...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PL (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006069-39 Sponsor Protocol Number: LPS16141 Start Date*: 2022-06-26
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Randomized, Double-Blind, Parallel-Group Clinical Trial to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care Versus Placebo Added to Standard of Care, in Non-Alcoho...
    Medical condition: Non-alcoholic fatty liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004871 10082249 Nonalcoholic fatty liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001774-24 Sponsor Protocol Number: 3574 Start Date*: 2006-09-13
    Sponsor Name:Newcastle u Tyne Hospitals NHS Trust
    Full Title: INTESTINAL MICRO-ORGANISMS IN THE PATHOGENESIS OF NASH AND THE ROLE OF MODULATION OF ENTERIC BACTERIA IN TREATMENT.
    Medical condition: Non alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-003766-26 Sponsor Protocol Number: 25-12-59 Start Date*: 2009-10-12
    Sponsor Name:Southampton University Hospitals NHS Trust
    Full Title: The effects of purified n-3 fatty acids on serum biomarkers and cardiovascular risk markers in a randomized placebo controlled trial in patients with non alcoholic fatty liver disease
    Medical condition: Non alcoholic fatty liver disease (NAFLD). This fatty liver disease may progress to a chronic condition that sometimes deteriorates further to cirrhosis and even liver carcinoma. To date there is n...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10031743 Other chronic nonalcoholic liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004605-38 Sponsor Protocol Number: NUC-4/NAS Start Date*: 2015-02-11
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of non-alcoholic fatty liver di...
    Medical condition: Non-alcoholic fatty liver disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001371-37 Sponsor Protocol Number: GDM-TREAT Start Date*: 2012-07-10
    Sponsor Name:Dr. med. Tina Vilsbøll
    Full Title: The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous gestational diabetes mellitus
    Medical condition: Gestational diabetes mellitus Non-alcoholic fatty liver disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10018210 Gestational diabetes mellitus LLT
    20.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003168-37 Sponsor Protocol Number: CAIN457ADE15 Start Date*: 2019-12-04
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, multicenter, 24-week study of subcutaneous secukinumab to assess anti-interleukin-17A treatment in plaque psoriasis patients with coexisting non-alcoholic fatty liver di...
    Medical condition: plaque psoriasis with coexisting non-alcoholic fatty liver disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000220-19 Sponsor Protocol Number: 2.2 Start Date*: 2020-09-24
    Sponsor Name:Verein zur Förderung von Wissenschaft und Forschung an der 1. Med. Abteilung der Krankenanstalt Rudolfstiftung
    Full Title: Comparing effects of weight loss by Liraglutide 3.0 mg with conventional liver fasting in non-alcoholic fatty liver disease before bariatric surgery
    Medical condition: Obesity and NAFLD can increase the risk and complexity of bariatric surgery up to 20%. Reducing the weight and liver size before bariatric surgery improves the operation area and reduces complicati...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021368-13 Sponsor Protocol Number: MTQ-LD-001 Start Date*: 2010-09-28
    Sponsor Name:Antipodean Pharmaceuticals
    Full Title: A Double-blind Randomised Placebo-controlled Multicentre Study of 40mg MitoQ and Placebo for the Treatment of Participants with Raised Liver Enzymes due to Non-Alcoholic Fatty Liver Disease (NAFLD)
    Medical condition: Raised Liver Enzymes due to Non-Alcoholic Fatty Liver Disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005411-16 Sponsor Protocol Number: NASH-EX-1114 Start Date*: 2015-06-30
    Sponsor Name:Exalenz Bioscience Ltd.
    Full Title: Clinical Study of the BreathID® System to train the algorithm for the 13C-Octanoate Breath Test with or without the 13C-Methacetin Breath Test (OBT and MBT respectively) for correlation with histol...
    Medical condition: Patients with Non-Alcoholic Fatty Liver Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003172-32 Sponsor Protocol Number: MASH Start Date*: 2018-05-23
    Sponsor Name:Imperial College London
    Full Title: Maraviroc Add-On Therapy for Steatohepatitis in HIV – The MASH Study
    Medical condition: Non alcoholic steatohepatitis (NASH) in patients with HIV mono-infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000813-37 Sponsor Protocol Number: OCABSGS Start Date*: 2012-05-16
    Sponsor Name:Sahlgrenska Academy
    Full Title: Effects of obeticholic acid on hepatic fatty acid/triglyceride metabolism and hepatobiliary detoxification/elimination in morbidly obese and gallstone patients.
    Medical condition: Fatty liver disease, morbid obesity, gallstone disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003638-26 Sponsor Protocol Number: D5883C00004 Start Date*: 2014-12-03
    Sponsor Name:AstraZeneca AB
    Full Title: A double-blind randomized placebo-controlled, parallel-group 12 week study to investigate the effects of Epanova® and dapagliFlozin on liver Fat contEnt in type 2 diabetiC patienTs;
    Medical condition: Patients with type 2-diabetes who have Non-alcoholic fatty liver disease (NAFLD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002564-27 Sponsor Protocol Number: STH16037 Start Date*: 2013-01-31
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Pilot open study of testosterone replacement in non-alcoholic steatohepatitis
    Medical condition: Non alcoholic fatty liver disease (NAFLD) in men with low serum testosterone levels
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000596-17 Sponsor Protocol Number: AGO/GAS/05/01 Start Date*: 2005-08-04
    Sponsor Name:University Hospital Ghent
    Full Title: Dubbel blind gerandomiseerde studie waar metformine versus placebo toegediend worden in de behandeling van NASH bij patiënten die omwille van obesitas bariatrische chirurgie ondergaan.
    Medical condition: Obesitas
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005187-63 Sponsor Protocol Number: FM101-CTP2-001 Start Date*: 2021-04-14
    Sponsor Name:Future Medicine Co., Ltd.
    Full Title: A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
    Medical condition: Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver LLT
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 08:22:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA